Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
SAN DIEGO, Jan. 27, 2016 -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, Chief Executive Officer, will present at the Leerink Partners 5th Annual Global Healthcare Conference in New York City on Wednesday, February 10, 2016 at 3:30 p.m. ET.
A live webcast of the presentation will be available at http://ir.retrophin.com/events.cfm and archived for replay through Tuesday, May 10, 2016.
About Retrophin
Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company's approved products include Chenodal®, Cholbam®, and Thiola®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis (FSGS), pantothenate kinase-associated neurodegeneration (PKAN), nephrotic syndrome and others. For additional information, please visit www.retrophin.com.
Contact: Chris Cline, CFA Director, Investor Relations 646-564-3680 [email protected]
